Monitor the pending Korsana merger for shareholder vote and closing conditions in Q3 2026. The insider support agreements (~24.2% of shares committed to vote in favor) reduce deal risk but do not guarantee approval. No immediate trading catalyst from this filing.
Price Chart
Executive Summary
This is a routine 10-K/A amendment filed solely to include Part III items (director/officer info, executive compensation, beneficial ownership, related-party transactions, and auditor fees) that were omitted from the original 10-K because the company did not intend to file a proxy statement within 120 days. No financial statements were restated, no errors were corrected, and no financial data changed. The filing also discloses the pending merger with Korsana Biosciences, announced on April 1, 2026, with insider support agreements covering ~24.2% of outstanding shares.
Key Facts
- Amendment adds Part III items (10-14) to the original 10-K; no financial restatement or error correction
- Auditor remains Ernst & Young LLP; audit fees $385,000 for both 2025 and 2024
- Pending merger with Korsana Biosciences expected to close Q3 2026; directors/officers holding ~24.2% of shares entered support agreements
- CEO Regina Graul total compensation $572,153 in 2025; CFO Rhonda Chicko $408,978 as a consultant
- Director Peter Hecht beneficially owns 21.3% of common stock (including convertible preferred)
- March 2025 private placement raised $1.375M at $2.75/share; directors Hecht and Higgins participated
- No director received cash fees or new equity grants in 2025
Financial Impact
No financial impact — this amendment adds only governance and compensation disclosures. The pending merger with Korsana may be transformative but terms are not disclosed here.
Risk Factors
- Merger with Korsana may fail to close if shareholder approval or other conditions are not met
- Out-of-the-money stock options will be cancelled for no consideration at closing, potentially dilutive to option holders
- Micro-cap ($14M market cap) with limited liquidity — any news flow can cause outsized price moves
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 10-K/A Filing (Primary) | 0001193125-26-194204 |
| Document: cycn-ex31_3.htm | 0001193125-26-194204 |
| Document: cycn-ex31_4.htm | 0001193125-26-194204 |
| Document: 0001193125-26-194204-index-headers.html | 0001193125-26-194204 |
| Document: 0001193125-26-194204-index.html | 0001193125-26-194204 |
| Document: 0001193125-26-194204.txt | 0001193125-26-194204 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 7, 2026 20d ago | SC 13G/A | — | awaiting T+5 | — | — |
Sep 11, 2026 6w ago | 8-K | $3.47 | awaiting T+5 | — | — |
Sep 10, 2026 6w ago | 3 | $3.47 | awaiting T+5 | — | — |
Aug 27, 2026 8w ago | 8-K | $3.99 $4.96 | ▲ +24.31% | ▲ +24.04% | — |
Aug 10, 2026 11w ago | 425 | $3.57 $4.12 | ▲ +15.41% | ▲ +15.81% | — |
Aug 3, 2026 12w ago | 425 | $3.51 $3.57 | ▲ +1.71% | ▲ +1.81% | — |
Jul 27, 2026 13w ago | EFFECT | $3.50 $3.44 | ▼ −1.71% | ▼ −2.79% | — |
Jul 10, 2026 15w ago | 425 | $3.82 $3.64 | ▼ −4.71% | ▼ −3.93% | — |
Jun 9, 2026 20w ago | S-4/A | $3.09 $3.18 | ▼ −2.91% | ▲ +0.52% | — |
Apr 30, 2026 25w ago | 10-K/A | $3.31 $3.24 | ▼ −2.11% | ▼ −3.84% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers